Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russia Attracts More Multinational Pharmas As Emerging Markets Continue To Bloom

This article was originally published in PharmAsia News

Executive Summary

Indian drug maker Ranbaxy is moving swiftly to capitalize on Russian policies to encourage establishing a local production presence, signing a memorandum of understanding with Russia's Yaroslavl regional authority to help the province build a medical and pharmaceutical center. The "going local, going to regions" move could set a model for international pharma companies eying the Russian market, says a Russia biologics expert

You may also be interested in...



Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal

MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.

Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal

MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.

AstraZeneca To Break Ground In Russia As MNCs Build Stronger Base In The Country

Scheduled to break ground in April, AstraZeneca PLC's investment of more than $150 million into construction of a drug manufacturing plant in Russia indicates the U.K.-based firm's confidence and long-term commitment to the emerging Russian market

Related Content

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel